08Abr 2014

Denosumab increased significantly bone mass in all three dual X-ray absorptiometry standard sites, while alendronate did not at total hip.

No benefit was observed in men previously treated with alendronate who switched to denosumab treatment.

Autor: Planas Morin J, Celma Domenech A, Placer Santos J, Trilla Herrera E, Salvador Lacambra C,…

08Abr 2014

In our series, the plasma rich in growth factors showed better results than the teriparatide in the treatment of recurrent oral bisphosphonate-related osteonecrosis.

The aim of this study is to describe and compare the evolution of recurrent bisphosphonate-related osteonecrosis of the jaws (BRONJ) in patients treated with plasma rich in growth factors or teriparatide. Material and Methods: Two different types of treatments were applied in patients diagnosed of recurrent BRONJ in a referral hospital for 1.100.000 inhabitants. In the group A, plasma rich in growth factors was applied during the surgery. In the group B, the treatment consisted in the subcutaneous administration of teriparatide.

Autor: Pelaz A, Junquera L, Gallego L, García-Consuegra L, Junquera S, Gómez C.

08Abr 2014

Although the VFA approach showed a lower than expected prevalence of VF in our cohort,

its association with clinical and densitometric parameters may be useful to identify women at risk for developing fragility fractures and may therefore justify its use in longitudinal studies.

The high prevalence of minor vertebral deformities detected in patients with VF indicates the need to evaluate this type of deformity as a risk factor for further skeletal fractures.

Autor: Kanterewicz E, Puigoriol E, García-Barrionuevo J, Del Rio L

08Abr 2014

Within the limits of this study, our findings suggest that the intake of simvastatin is associated with increasing serum OPG concentrations and this could have a protective effect against bone destruction and periodontal clinical attachment loss.

The baseline systemic inflammatory state of hyperlipidemic patients is indicated by their increased erythrocyte sedimentation rate.

Autor: Magán-Fernández A, Papay-Ramírez L, Tomás J, Marfil-Alvarez R, Rizzo M, Bravo M, Mesa F.

08Abr 2014

The impact on the population of the different recommendations is enormous, varying from 17% to 80% of the population over 50 who would be tested

Although in men it seems that a clinical rationale exists between the presence of risk factors and the rates of BMD testing, this pattern does not seem to exist in women. One in 10 of the densitometric tests performed were inappropriate according to all the guidelines.

Autor: Hurtado I, Sanfélix-Gimeno G, Baixauli-Pérez C, Peiró S, Sanfélix-Genovés J.

08Abr 2014

The results suggest that deletions in the 6p25.1 locus may predispose to higher risk of fracture in a subset of populations of European origin;

larger and geographically restricted studies will be needed to confirm this regional association. This is a first step towards the evaluation of the role of rare CNVs in osteoporosis.

Autor: Oei L, Hsu YH, Styrkarsdottir U, Eussen BH, de Klein A, Peters MJ, Halldorsson B,…

08Abr 2014

The results highlight the PUFA metabolism differences between uninduced and induced MSC to differentiate into adipocytes and osteoblasts, besides the relevant role of the lipoxygenase gene expression in adipogenesis induction.

Autor: Casado-Díaz A, Ferreiro-Vera C, Priego-Capote F, Dorado G, Luque-de-Castro MD, Quesada-Gómez JM.

08Abr 2014

Gene candidate and genome-wide association studies have revealed tens of loci of susceptibility for osteoporosis.

The results underscore the significance of the LRP5 gene in bone metabolism and emphasize the significance of the replication of previous results in independent cohorts.

Autor: Panach L, Mifsut D, Tarín JJ, Cano A, García-Pérez MA.

08Abr 2014

Keeping in mind the premise “living longer, living better”, this commentary is the result of the thoughts, proposals and conclusions obtained after one year working in the framework of this network.

Osteoporosis is a worldwide disease with a very high prevalence in humans older than 50. The main clinical consequences are bone fractures, which often lead to patient disability or even death.

Autor: Arcos D, Boccaccini AR, Bohner M, Díez-Pérez A, Epple M, Gómez-Barrena E,…

08Abr 2014

After examining results for 10 different bone fracture sites, advanced age appeared the single best possibility for uniting several different sites, resulting in an empirically based composite fracture risk model.

Several fracture prediction models that combine fractures at different sites into a composite outcome are in current use. However, to the extent individual fracture sites have differing risk factor profiles, model discrimination is impaired.

Autor: Fitzgerald G, Compston JE, Chapurlat RD, Pfeilschifter J, Cooper C,